ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Associations of Stem Cell Markers with Lobular Involution in Benign Breast Tissue.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples.Cancer causes & control : CCC · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTerminal duct lobular unit (TDLU) involution has been linked to decreased breast cancer risk in some studies. Whether the number/activity of breast stem cells (SC) in noncancerous tissue may influence TDLU involution is unknown. We examined the associations of CD44, CD24, and aldehyde dehydrogenase family 1 member A1 (ALDH1A1) SC markers with TDLU involution.
methodsWe included 309 cancer-free women with biopsy-confirmed benign breast disease. IHC was performed using tissue microarrays. For each core, IHC expression was assessed using semiautomated software as the percentage of positively stained cells for each marker. Eight TDLU involution measures were assessed with an established computational pathology algorithm. Generalized linear regression was used to examine the associations of each marker (≥10% vs. <10%) with each TDLU involution measure (log-transformed), adjusted for breast cancer risk factors.
resultsCD44 was positively associated with acini counts per nonadipose tissue area [epithelial: β = 0.307 (95% confidence interval, 0.072-0.542); stromal: β = 0.249 (0.005-0.494)] and median acini density [epithelial: β = 0.127 (0.025-0.229); stromal: β = 0.143 (0.037-0.249)]. Epithelial ALDH1A1 was positively associated with median acini density [β = 0.161 (0.045-0.278)], and stromal ALDH1A1 was positively associated with median acini counts per TDLU [β = 0.145 (0.018-0.273)].
conclusionsHigher CD44 and ALDH1A1 expressions in epithelial and stromal regions were associated with lower TDLU involution. IMPACT: We present the first epidemiologic evidence of the association of SC markers with TDLU involution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.